Literature DB >> 24632983

First report of digital skin ulcer with Stenotrophomonas maltophilia infection in an immunocompetent patient.

Emilio Trignano1, Matteo Jacopo Manzo, Nefer Fallico, Matteo Maffei, Francesco Marongiu, Gian Vittorio Campus, Corrado Rubino.   

Abstract

Stenotrophomonas maltophilia is an aerobic Gram-negative bacillus that usually causes infection in immunocompromised patients. We present the case of an immunocompetent patient with a distal necrosis of the second and third fingers of the right hand caused by S. maltophilia infection. The patient underwent antibiotic therapy with trimethoprim/sulphamethoxazole on the basis of the susceptibility tests and underwent surgical debridement of the necrotic tissues, including of the distal phalanx bone, and further reconstruction with Atasoy flap. Stenotrophomonas maltophilia is emerging as an important cause of skin infection in immunoresponsive patients. Several community-acquired infections have been reported, however, as far as we are aware of, our case represents the first report of a digital wound of intact skin caused by community-acquired S. maltophilia infection in an immunocompetent patient.

Entities:  

Keywords:  Digital skin ulcer; Stenotrophomonas maltophilia; immunocompetent patient

Mesh:

Substances:

Year:  2014        PMID: 24632983

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  11 in total

1.  Stenotrophomonas maltophilia Encodes a VirB/VirD4 Type IV Secretion System That Modulates Apoptosis in Human Cells and Promotes Competition against Heterologous Bacteria, Including Pseudomonas aeruginosa.

Authors:  Megan Y Nas; Richard C White; Ashley L DuMont; Alberto E Lopez; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2019-08-21       Impact factor: 3.441

2.  Type II Secretion-Dependent Degradative and Cytotoxic Activities Mediated by Stenotrophomonas maltophilia Serine Proteases StmPr1 and StmPr2.

Authors:  Ashley L DuMont; Sara M Karaba; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

3.  Stenotrophomonas maltophilia: an emerging multidrug-resistant opportunistic pathogen in the immunocompromised host.

Authors:  Emily Baumrin; Evan W Piette; Robert G Micheletti
Journal:  BMJ Case Rep       Date:  2017-12-20

Review 4.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

5.  Stenotrophomonas maltophilia Serine Protease StmPr1 Induces Matrilysis, Anoikis, and Protease-Activated Receptor 2 Activation in Human Lung Epithelial Cells.

Authors:  Ashley L DuMont; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2017-11-17       Impact factor: 3.441

Review 6.  Stenotrophomonas maltophilia as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic Therapy.

Authors:  Anthony A Adegoke; Thor A Stenström; Anthony I Okoh
Journal:  Front Microbiol       Date:  2017-11-30       Impact factor: 5.640

7.  Stenotrophomonas maltophilia: An Emerging Pathogen of the Respiratory Tract.

Authors:  Tejaswi Kanderi; Isha Shrimanker; Qurat Mansoora; Kajol Shah; Anna Yumen; Saketram Komanduri
Journal:  Am J Case Rep       Date:  2020-05-25

8.  Advances in the Microbiology of Stenotrophomonas maltophilia.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2021-05-26       Impact factor: 50.129

9.  Antibacterial Activity of Stenotrophomonas maltophilia Endolysin P28 against both Gram-positive and Gram-negative Bacteria.

Authors:  Hongling Dong; Chaoyang Zhu; Jingyi Chen; Xing Ye; Yu-Ping Huang
Journal:  Front Microbiol       Date:  2015-11-24       Impact factor: 5.640

10.  Stenotrophomonas maltophilia periprosthetic joint infection after reverse total shoulder arthroplasty.

Authors:  Michael E Hantes; Fotios Papageorgiou; George A Komnos
Journal:  IDCases       Date:  2020-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.